Health Care • Biotechnology: Pharmaceutical Preparations
$1.73 ▼ -0.01
(-0.57%)
MKT CAP: $29.3M • VOL: 40.8K
52W L $2 52W H $13
ROARABLE / RQD
D • 47/100
PIOTROSKI
2 / 9
RNAZ // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$28.0M | -$15.7M | -$19.4M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | -$34.7M | -$16.8M | -$18.5M |
| EBITDA (Normalized) | -$28.0M | -$15.6M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$19.5M | -$13.3M | -$18.1M |
| Capital Expenditures (CapEx) | $6.7K | $21.8K | — |
| Free Cash Flow (FCF) | -$19.5M | -$13.4M | -$18.1M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $17.8M | $5.8M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $10.3M | -$2.0M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR RNAZ.